# Bio-Techne Moat

Status: published. Policy: company-analysis-1.

Bio-Techne has specialized intellectual property, a broad product portfolio and demonstrated sole-manufacturer relationships that suggest customer dependency in parts of its business. The passages do not establish the breadth or duration of switching barriers or sustained competitive superiority. Pricing power remains unproven, with disclosed purchasing pressure and mixed margin resilience. This supports uncertainty rather than a finding of no moat.

## switching_costs

Being the sole manufacturer of products for many customers establishes current supplier dependency. OEM sales provide additional evidence of embedded commercial relationships, but neither disclosure establishes replacement costs or contractual exclusivity.

Durability: Sole-manufacturer dependency is disclosed in both fiscal 2024 and fiscal 2026. Its persistence supports a possible advantage, but affected revenue, qualification requirements and customer substitution histories are absent.

Risks: Customer consolidation increases purchasing pressure; larger suppliers may attract customers seeking a broader sole-source offering. Regulatory disruption could damage dependent customer relationships.

Invalidation: The switching-cost hypothesis would be undermined by customers routinely qualifying alternative manufacturers, transferring OEM business without meaningful disruption, or materially reducing purchases of these products.

Competitors: Not established
## intangible_assets

Existing patents, trade secrets, licenses and specialized products support differentiation. Actual product introductions demonstrate development activity, but do not establish protected market leadership or superior customer economics.

Durability: Potential durability depends on enforceable product-specific protection and continued commercially successful innovation. Patent lives, protected revenue and evidence of sustained customer preference are missing.

Risks: The issuer acknowledges that intellectual property does not always provide significant competitive advantage. Increased entry and low-cost competition can erode differentiation; product counts do not establish commercial success.

Invalidation: The advantage hypothesis would be undermined by competitors consistently matching protected functionality, material patent invalidations or design-arounds, or new products failing to sustain demand without price concessions.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/842023/000110465926100322/tech-20260630x10k.htm](https://www.sec.gov/Archives/edgar/data/842023/000110465926100322/tech-20260630x10k.htm) · 2026-08-24
- [https://www.sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm](https://www.sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm) · 2026-05-06
- [https://www.sec.gov/Archives/edgar/data/842023/000130817925000599/tech014339-def14a.htm](https://www.sec.gov/Archives/edgar/data/842023/000130817925000599/tech014339-def14a.htm) · 2025-09-19
- [https://www.sec.gov/Archives/edgar/data/842023/000155837025011716/tech-20250630x10k.htm](https://www.sec.gov/Archives/edgar/data/842023/000155837025011716/tech-20250630x10k.htm) · 2025-08-22
- [https://www.sec.gov/Archives/edgar/data/842023/000155837024012430/tech-20240630x10k.htm](https://www.sec.gov/Archives/edgar/data/842023/000155837024012430/tech-20240630x10k.htm) · 2024-08-22
- [https://www.sec.gov/Archives/edgar/data/842023/000110465926010335/tech-20251231x10q.htm](https://www.sec.gov/Archives/edgar/data/842023/000110465926010335/tech-20251231x10q.htm) · 2026-02-04

[JSON](https://beanvest.com/stock/tech/moat.json)